Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 48 of 48 publications.
Dawson KL, Price MA, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Mange B, Mansfield C, Comenencia-Ortiz E, Masaquel A, Ravelo A. Patient-reported disease burden and age: results from a national patient advocacy survey of patients with chronic lymphocytic leukemia, diffuse large-B-cell lymphoma and follicular lymphoma. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):4778. doi: 10.1182/blood-2019-123644.
Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AL, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano C, Williams VSL, Vissing J, Zhang Auberson L, Wu M, de Vera A, Papanicolaou DA, Amato AA, RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis: a phase 2b, randomised, double-blind, placebo-controlled study (RESILIENT). Lancet Neurol. 2019 Sep;18(9):834-44.
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711.
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400.